Danielle M. Greenawalt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Danielle M. Greenawalt has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
- Carlos Gomez-Roca
Department of Medical Oncology, Institut Claudius Regaud, Toulouse, France
13 shared publications - Chandrika Jeyamohan
14Bristol Myers Squibb, Princeton, New Jersey
13 shared publications - Giuseppe Curigliano
Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
13 shared publications - Jason John Luke
UPMC Hillman Cancer Center and University of Pittsburgh, Pittsburgh, PA
13 shared publications - Jayesh Desai
Peter MacCallum Cancer Centre, Melbourne, Australia
13 shared publications - Josep Tabernero
Medical Oncology Department, Vall d’Hebron University Hospital, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain
13 shared publications
Latest Publications
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined with Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies
Supplementary Figure S3. Outcomes in Patients With Bladder Cancer, Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Linrodostat Mesylate Plus Nivolumab During Dose Expansion
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined with Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies
Supplementary Figure S3. Outcomes in Patients With Bladder Cancer, Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Linrodostat Mesylate Plus Nivolumab During Dose Expansion
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined with Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies
Supplementary Figure S5. Baseline Kynurenine Levels in Patients Treated With Linrodostat Mesylate Plus Nivolumab by Response
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined with Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies
Supplementary Figure S5. Baseline Kynurenine Levels in Patients Treated With Linrodostat Mesylate Plus Nivolumab by Response
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined with Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies
Supplementary Figure S9. Survival Outcomes by IFN-γ Signature Score in Patients Treated With Linrodostat Mesylate Plus Nivolumab
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined with Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies
Supplementary Figure S9. Survival Outcomes by IFN-γ Signature Score in Patients Treated With Linrodostat Mesylate Plus Nivolumab
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S22 from Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined with Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies
Supplementary Table S1. Prior Therapy Eligibility Criteria for Patients Treated With Linrodostat Mesylate Plus Nivolumab During Dose Expansion (Part 2) and Patients Treated With Linrodostat Mesylate Plus Nivolumab and Ipilimumab (Part 3) Supplementary Table S2. Baseline Characteristics of and Prior Therapies in Patients Treated With Linrodostat Mesylate Plus Nivolumab During Dose Escalation Supplementary Table S3. Baseline Characteristics of and Prior Therapies in Patients Treated With Linrodostat Mesylate Plus Nivolumab During Dose Expansion Supplementary Table S4. Baseline Characteristics of and Prior Therapies in Patients Treated With Linrodostat Mesylate Plus Nivolumab and Ipilimumab Supplementary Table S5. Representativeness of Study Participants Supplementary Table S6. Exposure and Disposition in Patients Treated With Linrodostat Mesylate Plus Nivolumab During Dose Escalation and Clinical Pharmacology Substudies Supplementary Table S7. Exposure and Disposition in Patients Treated With Linrodostat Mesylate Plus Nivolumab During Dose Expansion Supplementary Table S8. Exposure and Disposition in Patients Treated With Linrodostat Mesylate Plus Nivolumab and Ipilimumab Supplementary Table S9. Safety Summary for Patients Treated With Linrodostat Mesylate Plus Nivolumab During Dose Escalation Supplementary Table S10. Liver- and Thyroid-Related Laboratory Abnormalitiesa Reported in Patients Treated With Linrodostat Mesylate Plus Nivolumab During Dose Escalation Supplementary Table S11. Safety Summary for Patients Treated With Linrodostat Mesylate Plus Nivolumab During Dose Expansion and Linrodostat Mesylate Plus Nivolumab and Ipilimumab Supplementary Table S12. All-Cause AEs Reported in >15% of Patients Treated With Linrodostat Mesylate Plus Nivolumab During Dose Expansion Supplementary Table S13. Immune-Related AEs Reported in Patients Treated With Linrodostat Mesylate Plus Nivolumab During Dose Escalation and Linrodostat Mesylate Plus Nivolumab and Ipilimumab Supplementary Table S14. Liver- and Thyroid-Related Laboratory Abnormalitiesa Reported in Patients Treated With Linrodostat Mesylate Plus Nivolumab During Dose Escalation and Linrodostat Mesylate Plus Nivolumab and Ipilimumab Supplementary Table S15. All-Cause AEs Reported in >15% of Patients Treated With Linrodostat Mesylate Plus Nivolumab and Ipilimumab Supplementary Table S16. Antitumor Activity per Investigator Review in Patients Treated With Linrodostat Mesylate Plus Nivolumab During Dose Escalation Supplementary Table S17. Antitumor Activity per Investigator Review in Patients Treated With Linrodostat Mesylate Plus Nivolumab During Dose Expansion Supplementary Table S18. Antitumor Activity per Investigator Review in Patients Treated With Linrodostat Mesylate Plus Nivolumab and Ipilimumab Supplementary Table S19. Response per Investigator Review by PD-L1 Status in Patients Treated With Linrodostat Mesylate Plus Nivolumab During Dose Escalation Supplementary Table S20. Response per Investigator Review by PD-L1 Status in Patients Treated With Linrodostat Mesylate Plus Nivolumab During Dose Expansion Supplementary Table S21. Response per Investigator Review by PD-L1 Status in Patients Treated With Linrodostat Mesylate Plus Nivolumab Plus Ipilimumab Supplementary Table S22. Comparison of Baseline Characteristics of and Prior Therapies in All Patients Treated With Linrodostat Mesylate Plus Nivolumab Versus Those in Patients in the Biomarker Cohort
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S22 from Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined with Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies
Supplementary Table S1. Prior Therapy Eligibility Criteria for Patients Treated With Linrodostat Mesylate Plus Nivolumab During Dose Expansion (Part 2) and Patients Treated With Linrodostat Mesylate Plus Nivolumab and Ipilimumab (Part 3) Supplementary Table S2. Baseline Characteristics of and Prior Therapies in Patients Treated With Linrodostat Mesylate Plus Nivolumab During Dose Escalation Supplementary Table S3. Baseline Characteristics of and Prior Therapies in Patients Treated With Linrodostat Mesylate Plus Nivolumab During Dose Expansion Supplementary Table S4. Baseline Characteristics of and Prior Therapies in Patients Treated With Linrodostat Mesylate Plus Nivolumab and Ipilimumab Supplementary Table S5. Representativeness of Study Participants Supplementary Table S6. Exposure and Disposition in Patients Treated With Linrodostat Mesylate Plus Nivolumab During Dose Escalation and Clinical Pharmacology Substudies Supplementary Table S7. Exposure and Disposition in Patients Treated With Linrodostat Mesylate Plus Nivolumab During Dose Expansion Supplementary Table S8. Exposure and Disposition in Patients Treated With Linrodostat Mesylate Plus Nivolumab and Ipilimumab Supplementary Table S9. Safety Summary for Patients Treated With Linrodostat Mesylate Plus Nivolumab During Dose Escalation Supplementary Table S10. Liver- and Thyroid-Related Laboratory Abnormalitiesa Reported in Patients Treated With Linrodostat Mesylate Plus Nivolumab During Dose Escalation Supplementary Table S11. Safety Summary for Patients Treated With Linrodostat Mesylate Plus Nivolumab During Dose Expansion and Linrodostat Mesylate Plus Nivolumab and Ipilimumab Supplementary Table S12. All-Cause AEs Reported in >15% of Patients Treated With Linrodostat Mesylate Plus Nivolumab During Dose Expansion Supplementary Table S13. Immune-Related AEs Reported in Patients Treated With Linrodostat Mesylate Plus Nivolumab During Dose Escalation and Linrodostat Mesylate Plus Nivolumab and Ipilimumab Supplementary Table S14. Liver- and Thyroid-Related Laboratory Abnormalitiesa Reported in Patients Treated With Linrodostat Mesylate Plus Nivolumab During Dose Escalation and Linrodostat Mesylate Plus Nivolumab and Ipilimumab Supplementary Table S15. All-Cause AEs Reported in >15% of Patients Treated With Linrodostat Mesylate Plus Nivolumab and Ipilimumab Supplementary Table S16. Antitumor Activity per Investigator Review in Patients Treated With Linrodostat Mesylate Plus Nivolumab During Dose Escalation Supplementary Table S17. Antitumor Activity per Investigator Review in Patients Treated With Linrodostat Mesylate Plus Nivolumab During Dose Expansion Supplementary Table S18. Antitumor Activity per Investigator Review in Patients Treated With Linrodostat Mesylate Plus Nivolumab and Ipilimumab Supplementary Table S19. Response per Investigator Review by PD-L1 Status in Patients Treated With Linrodostat Mesylate Plus Nivolumab During Dose Escalation Supplementary Table S20. Response per Investigator Review by PD-L1 Status in Patients Treated With Linrodostat Mesylate Plus Nivolumab During Dose Expansion Supplementary Table S21. Response per Investigator Review by PD-L1 Status in Patients Treated With Linrodostat Mesylate Plus Nivolumab Plus Ipilimumab Supplementary Table S22. Comparison of Baseline Characteristics of and Prior Therapies in All Patients Treated With Linrodostat Mesylate Plus Nivolumab Versus Those in Patients in the Biomarker Cohort
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined with Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies
Supplementary Figure S4. Change in Kynurenine and Tryptophan Levels From Baseline in Patients Treated With Linrodostat Mesylate Plus Nivolumab
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined with Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies
Supplementary Figure S4. Change in Kynurenine and Tryptophan Levels From Baseline in Patients Treated With Linrodostat Mesylate Plus Nivolumab
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined with Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies
Supplementary Figure S8. Survival Outcomes by Kynurenine Levels in Patients Treated With Linrodostat Mesylate Plus Nivolumab
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined with Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies
Supplementary Figure S8. Survival Outcomes by Kynurenine Levels in Patients Treated With Linrodostat Mesylate Plus Nivolumab
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Data from Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined with Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies
Purpose:To evaluate the safety, efficacy, pharmacokinetics, pharmacodynamics, and biomarkers of linrodostat mesylate, a selective, oral indoleamine 2,3-dioxygenase 1 inhibitor combined with nivolumab ± ipilimumab in advanced solid tumors and hematologic malignancies.Patients and Methods:In this phase 1/2 study, patients received once-daily linrodostat [part 1 (escalation), 25–400 mg; part 2 (expansion), 100 or 200 mg] plus nivolumab (480 mg every 4 weeks or 240 mg every 2 weeks) or triplet therapy (part 3, linrodostat 20–100 mg once daily; nivolumab 360 mg every 3 weeks or 480 mg every 4 weeks; ipilimumab 1 mg/kg every 6 weeks or every 8 weeks). Endpoints included safety and efficacy (coprimary; parts 2 and 3), pharmacokinetics, pharmacodynamics, biomarkers, and efficacy (part 1).Results:A total of 55, 494, and 41 patients were enrolled in parts 1, 2, and 3, respectively. Linrodostat exposures exceeded predicted therapeutic target concentrations starting at 50 mg. Rates of grade 3/4 adverse events were 50.1% to 63.4%. The maximum tolerated linrodostat dose was 200 mg; dose-limiting toxicities were primarily immune-related. Responses were observed across different cohorts, study parts, and tumor types, particularly in immunotherapy-naïve patients. Kynurenine decreased with linrodostat + nivolumab regardless of response. In contrast, IFN-γ gene expression signature was associated with response; in nonmelanoma patients, a composite of low tryptophan 2,3-dioxygenase gene expression plus high IFN-γ signature was associated with response.Conclusions:Linrodostat + nivolumab ± ipilimumab demonstrated a manageable safety profile. Kynurenine changes supported indoleamine 2,3-dioxygenase 1 pathway inhibition but did not correlate with response. A composite biomarker of low tryptophan 2,3-dioxygenase expression plus high IFN-γ gene expression may predict response to linrodostat + nivolumab.See related commentary by Zang and Dorff, p. 2077
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined with Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies
Purpose:To evaluate the safety, efficacy, pharmacokinetics, pharmacodynamics, and biomarkers of linrodostat mesylate, a selective, oral indoleamine 2,3-dioxygenase 1 inhibitor combined with nivolumab ± ipilimumab in advanced solid tumors and hematologic malignancies.Patients and Methods:In this phase 1/2 study, patients received once-daily linrodostat [part 1 (escalation), 25–400 mg; part 2 (expansion), 100 or 200 mg] plus nivolumab (480 mg every 4 weeks or 240 mg every 2 weeks) or triplet therapy (part 3, linrodostat 20–100 mg once daily; nivolumab 360 mg every 3 weeks or 480 mg every 4 weeks; ipilimumab 1 mg/kg every 6 weeks or every 8 weeks). Endpoints included safety and efficacy (coprimary; parts 2 and 3), pharmacokinetics, pharmacodynamics, biomarkers, and efficacy (part 1).Results:A total of 55, 494, and 41 patients were enrolled in parts 1, 2, and 3, respectively. Linrodostat exposures exceeded predicted therapeutic target concentrations starting at 50 mg. Rates of grade 3/4 adverse events were 50.1% to 63.4%. The maximum tolerated linrodostat dose was 200 mg; dose-limiting toxicities were primarily immune-related. Responses were observed across different cohorts, study parts, and tumor types, particularly in immunotherapy-naïve patients. Kynurenine decreased with linrodostat + nivolumab regardless of response. In contrast, IFN-γ gene expression signature was associated with response; in nonmelanoma patients, a composite of low tryptophan 2,3-dioxygenase gene expression plus high IFN-γ signature was associated with response.Conclusions:Linrodostat + nivolumab ± ipilimumab demonstrated a manageable safety profile. Kynurenine changes supported indoleamine 2,3-dioxygenase 1 pathway inhibition but did not correlate with response. A composite biomarker of low tryptophan 2,3-dioxygenase expression plus high IFN-γ gene expression may predict response to linrodostat + nivolumab.See related commentary by Zang and Dorff, p. 2077
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined with Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies
Supplementary Figure S6. Kynurenine at Baseline and Cycle 1, Day 15 in Patients Treated With Linrodostat Mesylate Plus Nivolumab by Response
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined with Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies
Supplementary Figure S6. Kynurenine at Baseline and Cycle 1, Day 15 in Patients Treated With Linrodostat Mesylate Plus Nivolumab by Response
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined with Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies
Supplementary Figure S2. Pharmacokinetic and Biomarker Sampling Schedules by Study Part
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined with Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies
Supplementary Figure S2. Pharmacokinetic and Biomarker Sampling Schedules by Study Part